PeptideStack
5.2kquestions
20kanswers
220users

clinical-trials

Page 5 of 32 · 745 questions tagged clinical-trials.

745 questions · sorted by votes · page 5 of 32

33 votes0 answers33k views
Why do two papers on PIONEER-1 report different headline figures?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I want to know whether this is a real physical effect or an…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by noor_alhassan 11k · 19 months ago
33 votes0 answers25k views
Why do two papers on SURMOUNT-OSA report different headline figures?

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I keep seeing this stated as a fact with no explanation…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by juan_esquivel 14k · 19 months ago
33 votes 5 answers24k views
What does TRIUMPH-3 tell me about constipation at the 4 mg dose?

Details up front: TRIUMPH-3 · constipation · 4 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by forty_units 16k · 12 months ago
33 votes 5 answers23k views
How do I convert the TRIUMPH-3 hazard ratio into an absolute risk reduction?

My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I want the working, not the result — I need to be able to redo it…

cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by low_dead_space 37k · 17 months ago
33 votes 3 answers13k views
SELECT reported HR 0.80 for MACE. What does that actually license me to conclude?

I keep seeing SELECT summarised as "semaglutide cuts heart attacks and strokes by 20%". I understand that 20% comes from the hazard ratio of 0.80, and I understand…

semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
cardiovascular
cardiovascular

Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk…

68 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by sinead_gaffney 28k · 23 months ago
32 votes 5 answers59k views
Is there any published stability data for mazdutide at minus 20 °C?

Details up front: mazdutide · minus 20 °C. I would rather be corrected now than propagate something wrong. I am specifically not interested in a testimonial; I am…

peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

908 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

701 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
mazdutide
mazdutide

A GLP-1 and glucagon receptor dual agonist developed primarily in China, with a distinct dose range and a fast-moving publication record.…

237 questions
asked by vial_five 12k · 23 months ago
32 votes5 answers45k views
How comparable are oral semaglutide and liraglutide on the evidence available?

What I am working with: oral semaglutide · liraglutide. The comparison I want does not seem to exist anywhere in a form I can evaluate. I have read the arguments for…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
oral-glp1
oral-glp1

Oral routes for GLP-1 receptor agonism: peptide formulations rescued by absorption enhancers such as SNAC, and true small molecules that need no…

219 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
asked by tare_weight 60k · 16 months ago
32 votes 5 answers43k views
What did the placebo arm of SURMOUNT-2 report for hair thinning?

What I have: SURMOUNT-2 · hair thinning. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
hair-loss
hair-loss

Telogen effluvium following rapid weight loss versus a drug-attributable effect: the timing signature that distinguishes them, protein and…

50 questions
asked by esben_lykke 84k · 22 months ago
32 votes0 answers39k views
What does ATTAIN-1 tell me about early satiety at the 12 mg dose?

Details up front: ATTAIN-1 · early satiety · 12 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by aine_mulcahy 28k · 23 months ago
32 votes 2 answers37k views
Is 7.5 mg weekly a defensible maintenance dose for a GLP-1 receptor agonist?

What I am working with: 7.5 mg · a GLP-1 receptor agonist. I am trying to build something sustainable rather than something thorough that I will abandon. I have…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by tenth_of_a_unit 57k · 16 months ago
32 votes 2 answers35k views
What does ESSENCE tell me about constipation at the 1 mg dose?

Details up front: ESSENCE · constipation · 1 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
constipation
constipation

Slowed transit as a consequence of delayed gastric emptying and reduced intake: incidence figures, fibre and hydration evidence, and why it often…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by vial_five 12k · 2.3 years ago
32 votes 2 answers34k views
Is 12 mg weekly a defensible maintenance dose for retatrutide?

What I have: 12 mg · retatrutide. I would rather over-plan the first cycle and simplify later. I am prepared to do the work if someone can tell me which work matters.…

maintenance-dose
maintenance-dose

Staying put: the lowest dose that holds a result, the difference between the maximum studied dose and the maximum useful dose, and what the…

54 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by claudia_ferrante 22k · 14 months ago
32 votes5 answers31k views
What is a treatment-policy estimand and why does it change the number?

I am reading the trial table rather than the press release, which is why the numbers differ. I can predict the outcome but I cannot explain it, which means I will get…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
asked by k_szabo 27k · 12 months ago
32 votes0 answers29k views
What did the placebo arm of PIONEER-1 report for headache?

Numbers first: PIONEER-1 · headache. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
asked by bufferline42 30k · 16 months ago
32 votes0 answers26k views
What does SURMOUNT-2 tell me about nausea at the 10 mg dose?

Numbers first: SURMOUNT-2 · nausea · 10 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by j_wierzbicki 69k · 22 months ago
32 votes 5 answers24k views
How comparable are retatrutide and cagrilintide on the evidence available?

The particulars: retatrutide · cagrilintide. I suspect the honest answer is that it depends, in which case I would like to know on what. Assume I can obtain either…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
amylin
amylin

Amylin and its analogues, most prominently cagrilintide, as a satiety mechanism orthogonal to incretin signalling. Includes the pharmacology of…

237 questions
asked by wren_calloway 23k · 15 months ago
32 votes0 answers12k views
What did the placebo arm of STEP 2 report for nausea?

For reference: STEP 2 · nausea. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am being…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
nausea
nausea

The dominant tolerability signal in every trial of the class: incidence, timing relative to a dose step, duration, and the distinction between…

55 questions
asked by sasha_ferreira 9.4k · 12 months ago
31 votes 5 answers52k views
Does a slower rate of loss reduce gallstone risk in practice?

For the avoidance of doubt, nothing here is urgent — I would be in a clinic rather than a text box. This is one of those things that everyone repeats and nobody…

gallbladder
gallbladder

Cholelithiasis and cholecystitis risk during rapid weight loss and on treatment: how much is attributable to the rate of loss versus to the drug,…

8 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
asked by ines_delacruz 16k · 20 months ago
31 votes 5 answers35k views
Does the TRIUMPH-3 population resemble anyone asking about retatrutide here?

The case in front of me: TRIUMPH-3 · retatrutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by dead_volume 56k · 12 months ago
31 votes 4 answers30k views
What does SUSTAIN-6 tell me about reflux at the 2 mg dose?

Setup, so nobody has to ask: SUSTAIN-6 · reflux · 2 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by ines_brandt 113k · 2.1 years ago
31 votes5 answers25k views
What did the placebo arm of SURMOUNT-2 report for reflux?

Stated plainly: SURMOUNT-2 · reflux. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by area_percent 9.9k · 2.1 years ago
31 votes 5 answers22k views
What does ESSENCE report at the 2.4 mg dose level?

Concretely: ESSENCE · 2.4 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which I…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
dosing-math
dosing-math

The arithmetic itself: milligrams to millilitres to insulin units, concentration after reconstitution, dose per draw, and vial-days per vial. Show…

764 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by Dr_Fatima_Belkacem 18k · 13 months ago
31 votes 5 answers19k views
What does SURMOUNT-1 tell me about headache at the 5 mg dose?

What I have: SURMOUNT-1 · headache · 5 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by tess_amankwah 22k · 14 months ago
31 votes 5 answers15k views
What does STEP 1 tell me about dizziness at the 2.4 mg dose?

Stated plainly: STEP 1 · dizziness · 2.4 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by w_okoye 43k · 10 months ago